TREMFYA
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREMFYA (guselkumab) is a monoclonal antibody that selectively blocks interleukin-23 (IL-23), a key cytokine driving inflammatory skin diseases. It is approved for moderate-to-severe plaque psoriasis and psoriatic arthritis, with efficacy demonstrated in reducing inflammatory markers and clinical symptoms. The IL-23 antagonist mechanism represents a targeted approach to immune-mediated dermatological conditions.
$531MPart D
PeakStable
Product is at peak commercial maturity with $531M in annual Part D spending; team size and investment likely stable to slightly declining as competition intensifies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Started Aug 2026
10 enrolled
PsoriasisColitis, UlcerativeCrohn Disease+1 more
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
Started Aug 2021
327 enrolled
Psoriasis
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
Started Nov 2013
200 enrolled
PsoriasisPregnancyPsoriatic Arthritis+1 more
Why This Matters for Your Career
Worked on TREMFYA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.